These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 31352077)
41. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Keam SJ; Keating GM Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163 [TBL] [Abstract][Full Text] [Related]
42. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer. Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC AAPS PharmSciTech; 2003 Oct; 4(4):E54. PubMed ID: 15198549 [TBL] [Abstract][Full Text] [Related]
43. In vitro validation of a Respimat® adapter for delivery of inhaled bronchodilators during mechanical ventilation. Dellweg D; Wachtel H; Höhn E; Pieper MP; Barchfeld T; Köhler D; Glaab T J Aerosol Med Pulm Drug Deliv; 2011 Dec; 24(6):285-92. PubMed ID: 21870959 [TBL] [Abstract][Full Text] [Related]
44. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes. Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563 [TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143 [TBL] [Abstract][Full Text] [Related]
46. Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler. Biswas R; Hanania NA; Sabharwal A J Aerosol Med Pulm Drug Deliv; 2017 Aug; 30(4):256-266. PubMed ID: 28157430 [TBL] [Abstract][Full Text] [Related]
48. Real-Time Analysis of the Respiratory Flow Through a Valved Holding Chamber. Curran E; Porée T; Rubin BK J Aerosol Med Pulm Drug Deliv; 2020 Aug; 33(4):205-213. PubMed ID: 32101063 [No Abstract] [Full Text] [Related]
49. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study. Janson C; Lööf T; Telg G; Stratelis G; Nilsson F NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177 [TBL] [Abstract][Full Text] [Related]
50. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers. Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743 [TBL] [Abstract][Full Text] [Related]
51. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD. Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436 [TBL] [Abstract][Full Text] [Related]
52. The Respimat Soft Mist Inhaler, a Novel Inhaled Drug Delivery Device. Perriello EA; Sobieraj DM Conn Med; 2016; 80(6):359-64. PubMed ID: 27509644 [TBL] [Abstract][Full Text] [Related]
53. The clinical relevance of dry powder inhaler performance for drug delivery. Demoly P; Hagedoorn P; de Boer AH; Frijlink HW Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253 [TBL] [Abstract][Full Text] [Related]
54. Safety, tolerability, and plasma exposure of tiotropium Respimat® in children and adults with cystic fibrosis. Konstan MW; Sharma A; Moroni-Zentgraf P; Wang F; Koker P J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):137-44. PubMed ID: 25380193 [TBL] [Abstract][Full Text] [Related]
55. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD]. Henriet AC; Marchand-Adam S; Mankikian J; Diot P Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393 [TBL] [Abstract][Full Text] [Related]
56. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler. Hodder R; Pavia D; Dewberry H; Alexander K; Iacono P; Ponitz H; Beck E Respir Med; 2005 Sep; 99(9):1087-95. PubMed ID: 15893465 [TBL] [Abstract][Full Text] [Related]
57. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients. Ichinose M; Fujimoto T; Fukuchi Y Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446 [TBL] [Abstract][Full Text] [Related]
58. Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair Yildiz P; Bayraktaroglu M; Gorgun D; Secik F Int J Chron Obstruct Pulmon Dis; 2016; 11():2859-2867. PubMed ID: 27920513 [TBL] [Abstract][Full Text] [Related]
59. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. Pitcairn G; Reader S; Pavia D; Newman S J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001 [TBL] [Abstract][Full Text] [Related]
60. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy. Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]